Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction

Eli Lilly is hoping to relieve pain for both shareholders and patients with its new pipeline of pain drugs.

The Indianapolis-based drugmaker is in the news on Wednesday as the FDA approval of its migraine drug Emgality for cluster headache treatment has flipped the script from 2018, wherein the pharmaceutical giant reached approval stage for Emgality's migraine treatments later than both Teva Pharmaceutical's Ajovy drug and Amgen's Aimovig.